Search

Your search keyword '"Libby, Edward N"' showing total 8 results
Start Over Author "Libby, Edward N" Publisher wiley
8 results on '"Libby, Edward N"'

2. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial

Author

Budde, Lihua E., primary, Wu, David, additional, Martin, Daniel B., additional, Philip, Mary, additional, Shustov, Andrei R., additional, Smith, Stephen D., additional, Gooley, Ted A., additional, Chen, Tara L., additional, Libby, Edward N., additional, Chen, Eric Y., additional, Kojouri, Kiarash, additional, Langerak, Alan, additional, Roden, Jennifer E., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2018
Full Text
View/download PDF

3. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

Author

Zent, Clive S., primary, Victoria Wang, Xin, additional, Ketterling, Rhett P., additional, Hanson, Curtis A., additional, Libby, Edward N., additional, Barrientos, Jacqueline C., additional, Call, Timothy G., additional, Chang, Julie E., additional, Liu, Jane J., additional, Calvo, Alejandro R., additional, Lazarus, Hillard M., additional, Rowe, Jacob M., additional, Luger, Selina M., additional, Litzow, Mark R., additional, and Tallman, Martin S., additional

Published
2016
Full Text
View/download PDF

4. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma

Author

Cassaday, Ryan D., primary, Stevenson, Philip A., additional, Gooley, Theodore A., additional, Chauncey, Thomas R., additional, Pagel, John M., additional, Rajendran, Joseph, additional, Till, Brian G., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Bensinger, William I., additional, Holmberg, Leona A., additional, Shustov, Andrei R., additional, Green, Damian J., additional, Smith, Stephen D., additional, Libby, Edward N., additional, Maloney, David G., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2015
Full Text
View/download PDF

5. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

Author

Mikhael, Joseph R., primary, Reeder, Craig B., additional, Libby, Edward N., additional, Costa, Luciano J., additional, Bergsagel, P. Leif, additional, Buadi, Francis, additional, Mayo, Angela, additional, Nagi Reddy, Sravan K., additional, Gano, Katherine, additional, Dueck, Amylou C., additional, and Stewart, A. Keith, additional

Published
2015
Full Text
View/download PDF

6. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

Author

Onishi, Maika, primary, Graf, Solomon A., additional, Holmberg, Leona, additional, Behnia, Sanaz, additional, Shustov, Andrei R., additional, Schiavo, Karen, additional, Philip, Mary, additional, Libby, Edward N., additional, Cassaday, Ryan D., additional, Pagel, John M., additional, Roden, Jennifer E., additional, Maloney, David G., additional, Green, Damian J., additional, Till, Brian G., additional, Press, Oliver W., additional, Smith, Stephen D., additional, and Gopal, Ajay K., additional

Published
2014
Full Text
View/download PDF

8. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.

Author

Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, and Lonial S

Subjects
Humans, Quality of Life, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Multiple Myeloma
Abstract

Background: Patients with relapsed/refractory multiple myeloma (RRMM) have a high unmet treatment need. Belantamab mafodotin (belamaf), a first-in-class, B-cell maturation antigen-binding antibody-drug conjugate, eliminates myeloma cells through direct cell killing and an anti-myeloma immune response., Methods: DREAMM-2 (NCT03525678) was a phase 2, two-arm, open-label trial in patients with heavily pretreated RRMM who had three or more prior therapies, were refractory to an immunomodulatory agent and a proteasome inhibitor, and refractory or intolerant to an anti-CD38 monoclonal antibody. Belamaf was given at 2.5 or 3.4 mg/kg every 3 weeks. The primary end point was overall response rate (ORR); secondary end points included progression-free survival (PFS), overall survival (OS), safety, ocular symptoms, and health-related quality of life (HRQOL)., Results: This final analysis (cutoff date, March 31, 2022), N = 223, with median follow-up of 12.5 and 13.8 months, demonstrated an ORR of 32% and 35%, median PFS of 2.8 and 3.9 months, and median OS of 15.3 and 14.0 months in the 2.5 mg/kg and 3.4 mg/kg cohorts, respectively. Median duration of response was 12.5 and 6.2 months. No new safety signals were observed; the most common Grade 3 and 4 adverse events were keratopathy (29% vs. 25%), thrombocytopenia (22% vs. 29%), and anemia (21% vs. 28%). HRQOL outcomes suggest that overall global health status/quality of life, physical and role functioning, and overall disease symptoms were maintained or improved during treatment., Conclusions: This final analysis of DREAMM-2 confirms that in patients with triple-class refractory RRMM, single-agent belamaf results in durable and clinically meaningful responses with a manageable safety profile., (© 2023 GSK and The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results